{"pmid":32470577,"title":"High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment.","text":["High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment.","The present-day world is severely suffering from the recently emerged SARS-CoV-2. The lack of prescribed drugs for the deadly virus has stressed the likely need to identify novel inhibitors to alleviate and stop the pandemic. In the present high throughput virtual screening study, we used in silico techniques like receptor-ligand docking, Molecular dynamic (MD), and ADME properties to screen natural compounds. It has been documented that many natural compounds display antiviral activities, including anti-SARS-CoV effect. The present study deals with compounds of Natural Product Activity and Species Source (NPASS) database with known biological activity that probably impedes the activity of six essential enzymes of the virus. Promising drug-like compounds were identified, demonstrating better docking score and binding energy for each druggable targets. After an extensive screening analysis, three novel multi-target natural compounds were predicted to subdue the activity of three/more major drug targets simultaneously. Concerning the utility of natural compounds in the formulation of many therapies, we propose these compounds as excellent lead candidates for the development of therapeutic drugs against SARS-CoV-2.","Int J Biol Macromol","Naik, Biswajit","Gupta, Nidhi","Ojha, Rupal","Singh, Satyendra","Prajapati, Vijay Kumar","Prusty, Dhaneswar","32470577"],"abstract":["The present-day world is severely suffering from the recently emerged SARS-CoV-2. The lack of prescribed drugs for the deadly virus has stressed the likely need to identify novel inhibitors to alleviate and stop the pandemic. In the present high throughput virtual screening study, we used in silico techniques like receptor-ligand docking, Molecular dynamic (MD), and ADME properties to screen natural compounds. It has been documented that many natural compounds display antiviral activities, including anti-SARS-CoV effect. The present study deals with compounds of Natural Product Activity and Species Source (NPASS) database with known biological activity that probably impedes the activity of six essential enzymes of the virus. Promising drug-like compounds were identified, demonstrating better docking score and binding energy for each druggable targets. After an extensive screening analysis, three novel multi-target natural compounds were predicted to subdue the activity of three/more major drug targets simultaneously. Concerning the utility of natural compounds in the formulation of many therapies, we propose these compounds as excellent lead candidates for the development of therapeutic drugs against SARS-CoV-2."],"journal":"Int J Biol Macromol","authors":["Naik, Biswajit","Gupta, Nidhi","Ojha, Rupal","Singh, Satyendra","Prajapati, Vijay Kumar","Prusty, Dhaneswar"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32470577","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.ijbiomac.2020.05.184","keywords":["covid-19","molecular docking","molecular dynamics","muti-target","natural compounds"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668167110044418048,"score":9.490897,"similar":[{"pmid":32408547,"title":"Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).","text":["Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused about 2 million infections and is responsible for more than 100,000 deaths worldwide. To date, there is no specific drug registered to combat the disease it causes, named coronavirus disease 2019 (COVID-19). In the current study, we used an in silico approach to screen natural compounds to find potent inhibitors of the host enzyme transmembrane protease serine 2 (TMPRSS2). This enzyme facilitates viral particle entry into host cells, and its inhibition blocks virus fusion with angiotensin-converting enzyme 2 (ACE2). This, in turn, restricts SARS-CoV-2 pathogenesis. A three-dimensional structure of TMPRSS2 was built using SWISS-MODEL and validated by RAMPAGE. The natural compounds library Natural Product Activity and Species Source (NPASS), containing 30,927 compounds, was screened against the target protein. Two techniques were used in the Molecular Operating Environment (MOE) for this purpose, i.e., a ligand-based pharmacophore approach and a molecular docking-based screening. In total, 2140 compounds with pharmacophoric features were retained using the first approach. Using the second approach, 85 compounds with molecular docking comparable to or greater than that of the standard inhibitor (camostat mesylate) were identified. The top 12 compounds with the most favorable structural features were studied for physicochemical and ADMET (absorption, distribution, metabolism, excretion, toxicity) properties. The low-molecular-weight compound NPC306344 showed significant interaction with the active site residues of TMPRSS2, with a binding energy score of -14.69. Further in vitro and in vivo validation is needed to study and develop an anti-COVID-19 drug based on the structures of the most promising compounds identified in this study.","Molecules","Rahman, Noor","Basharat, Zarrin","Yousuf, Muhammad","Castaldo, Giuseppe","Rastrelli, Luca","Khan, Haroon","32408547"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused about 2 million infections and is responsible for more than 100,000 deaths worldwide. To date, there is no specific drug registered to combat the disease it causes, named coronavirus disease 2019 (COVID-19). In the current study, we used an in silico approach to screen natural compounds to find potent inhibitors of the host enzyme transmembrane protease serine 2 (TMPRSS2). This enzyme facilitates viral particle entry into host cells, and its inhibition blocks virus fusion with angiotensin-converting enzyme 2 (ACE2). This, in turn, restricts SARS-CoV-2 pathogenesis. A three-dimensional structure of TMPRSS2 was built using SWISS-MODEL and validated by RAMPAGE. The natural compounds library Natural Product Activity and Species Source (NPASS), containing 30,927 compounds, was screened against the target protein. Two techniques were used in the Molecular Operating Environment (MOE) for this purpose, i.e., a ligand-based pharmacophore approach and a molecular docking-based screening. In total, 2140 compounds with pharmacophoric features were retained using the first approach. Using the second approach, 85 compounds with molecular docking comparable to or greater than that of the standard inhibitor (camostat mesylate) were identified. The top 12 compounds with the most favorable structural features were studied for physicochemical and ADMET (absorption, distribution, metabolism, excretion, toxicity) properties. The low-molecular-weight compound NPC306344 showed significant interaction with the active site residues of TMPRSS2, with a binding energy score of -14.69. Further in vitro and in vivo validation is needed to study and develop an anti-COVID-19 drug based on the structures of the most promising compounds identified in this study."],"journal":"Molecules","authors":["Rahman, Noor","Basharat, Zarrin","Yousuf, Muhammad","Castaldo, Giuseppe","Rastrelli, Luca","Khan, Haroon"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32408547","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/molecules25102271","keywords":["coronavirus","docking","drug design","natural product","serine protease"],"e_drugs":["Serine","camostat"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666897319103037440,"score":504.68323},{"pmid":32395606,"pmcid":"PMC7211761","title":"Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study.","text":["Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study.","The aim of this study was to develop an appropriate anti-viral drug against the SARS-CoV-2 virus. An immediately qualifying strategy would be to use existing powerful drugs from various virus treatments. The strategy in virtual screening of antiviral databases for possible therapeutic effect would be to identify promising drug molecules, as there is currently no vaccine or treatment approved against COVID-19. Targeting the main protease (pdb id: 6LU7) is gaining importance in anti-CoV drug design. In this conceptual context, an attempt has been made to suggest an in silico computational relationship between US-FDA approved drugs, plant-derived natural drugs, and Coronavirus main protease (6LU7) protein. The evaluation of results was made based on Glide (Schrodinger) dock score. Out of 62 screened compounds, the best docking scores with the targets were found for compounds: lopinavir, amodiaquine, and theaflavin digallate (TFDG). Molecular dynamic (MD) simulation study was also performed for 20 ns to confirm the stability behaviour of the main protease and inhibitor complexes. The MD simulation study validated the stability of three compounds in the protein binding pocket as potent binders.","Inform Med Unlocked","Peele, K Abraham","Chandrasai, P","Srihansa, T","Krupanidhi, S","Sai, A Vijaya","Babu, D John","Indira, M","Reddy, A Ranganadha","Venkateswarulu, T C","32395606"],"abstract":["The aim of this study was to develop an appropriate anti-viral drug against the SARS-CoV-2 virus. An immediately qualifying strategy would be to use existing powerful drugs from various virus treatments. The strategy in virtual screening of antiviral databases for possible therapeutic effect would be to identify promising drug molecules, as there is currently no vaccine or treatment approved against COVID-19. Targeting the main protease (pdb id: 6LU7) is gaining importance in anti-CoV drug design. In this conceptual context, an attempt has been made to suggest an in silico computational relationship between US-FDA approved drugs, plant-derived natural drugs, and Coronavirus main protease (6LU7) protein. The evaluation of results was made based on Glide (Schrodinger) dock score. Out of 62 screened compounds, the best docking scores with the targets were found for compounds: lopinavir, amodiaquine, and theaflavin digallate (TFDG). Molecular dynamic (MD) simulation study was also performed for 20 ns to confirm the stability behaviour of the main protease and inhibitor complexes. The MD simulation study validated the stability of three compounds in the protein binding pocket as potent binders."],"journal":"Inform Med Unlocked","authors":["Peele, K Abraham","Chandrasai, P","Srihansa, T","Krupanidhi, S","Sai, A Vijaya","Babu, D John","Indira, M","Reddy, A Ranganadha","Venkateswarulu, T C"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32395606","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.imu.2020.100345","keywords":["anti-malarial drugs","antiviral compounds","coronavirus","simulations"],"e_drugs":["theaflavin digallate","Lopinavir"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666627828015169537,"score":408.65384},{"pmid":32367767,"title":"Potential Inhibitors of Coronavirus 3-Chymotrypsin-Like Protease (3CL(pro)): An in silico screening of Alkaloids and Terpenoids from African medicinal plants.","text":["Potential Inhibitors of Coronavirus 3-Chymotrypsin-Like Protease (3CL(pro)): An in silico screening of Alkaloids and Terpenoids from African medicinal plants.","The novel coronavirus disease 2019 (COVID-19) caused by SARS-COV-2 has raised myriad of global concerns. There is currently no FDA approved antiviral strategy to alleviate the disease burden. The conserved 3-chymotrypsin-like protease (3CL(pro)), which controls coronavirus replication is a promising drug target for combating the coronavirus infection. This study screens some African plants derived alkaloids and terpenoids as potential inhibitors of coronavirus 3CL(pro) using in silico approach.Bioactive alkaloids (62) and terpenoids (100) of plants native to Africa were docked to the 3CL(pro) of the novel SARS-CoV-2. The top twenty alkaloids and terpenoids with high binding affinities to the SARS-CoV-2 3CL(pro) were further docked to the 3CL(pro) of SARS-CoV and MERS-CoV. The docking scores were compared with 3CL(pro)-referenced inhibitors (Lopinavir and Ritonavir). The top docked compounds were further subjected to ADEM/Tox and Lipinski filtering analyses for drug-likeness prediction analysis.This ligand-protein interaction study revealed that more than half of the top twenty alkaloids and terpenoids interacted favourably with the coronaviruses 3CL(pro), and had binding affinities that surpassed that of lopinavir and ritonavir. Also, a highly defined hit-list of seven compounds (10-Hydroxyusambarensine, Cryptoquindoline, 6-Oxoisoiguesterin, 22-Hydroxyhopan-3-one, Cryptospirolepine, Isoiguesterin and 20-Epibryonolic acid) were identified. Furthermore, four non-toxic, druggable plant derived alkaloids (10-Hydroxyusambarensine, and Cryptoquindoline) and terpenoids (6-Oxoisoiguesterin and 22-Hydroxyhopan-3-one), that bind to the receptor-binding site and catalytic dyad of SARS-CoV-2 3CL(pro) were identified from the predictive ADME/tox and Lipinski filter analysis. However, further experimental analyses are required for developing these possible leads into natural anti-COVID-19 therapeutic agents for combating the pandemic.","J Biomol Struct Dyn","Gyebi, Gideon A","Ogunro, Olalekan B","Adegunloye, Adegbenro P","Ogunyemi, Oludare M","Afolabi, Saheed O","32367767"],"abstract":["The novel coronavirus disease 2019 (COVID-19) caused by SARS-COV-2 has raised myriad of global concerns. There is currently no FDA approved antiviral strategy to alleviate the disease burden. The conserved 3-chymotrypsin-like protease (3CL(pro)), which controls coronavirus replication is a promising drug target for combating the coronavirus infection. This study screens some African plants derived alkaloids and terpenoids as potential inhibitors of coronavirus 3CL(pro) using in silico approach.Bioactive alkaloids (62) and terpenoids (100) of plants native to Africa were docked to the 3CL(pro) of the novel SARS-CoV-2. The top twenty alkaloids and terpenoids with high binding affinities to the SARS-CoV-2 3CL(pro) were further docked to the 3CL(pro) of SARS-CoV and MERS-CoV. The docking scores were compared with 3CL(pro)-referenced inhibitors (Lopinavir and Ritonavir). The top docked compounds were further subjected to ADEM/Tox and Lipinski filtering analyses for drug-likeness prediction analysis.This ligand-protein interaction study revealed that more than half of the top twenty alkaloids and terpenoids interacted favourably with the coronaviruses 3CL(pro), and had binding affinities that surpassed that of lopinavir and ritonavir. Also, a highly defined hit-list of seven compounds (10-Hydroxyusambarensine, Cryptoquindoline, 6-Oxoisoiguesterin, 22-Hydroxyhopan-3-one, Cryptospirolepine, Isoiguesterin and 20-Epibryonolic acid) were identified. Furthermore, four non-toxic, druggable plant derived alkaloids (10-Hydroxyusambarensine, and Cryptoquindoline) and terpenoids (6-Oxoisoiguesterin and 22-Hydroxyhopan-3-one), that bind to the receptor-binding site and catalytic dyad of SARS-CoV-2 3CL(pro) were identified from the predictive ADME/tox and Lipinski filter analysis. However, further experimental analyses are required for developing these possible leads into natural anti-COVID-19 therapeutic agents for combating the pandemic."],"journal":"J Biomol Struct Dyn","authors":["Gyebi, Gideon A","Ogunro, Olalekan B","Adegunloye, Adegbenro P","Ogunyemi, Oludare M","Afolabi, Saheed O"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32367767","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1080/07391102.2020.1764868","keywords":["covid-19","coronavirus 3clpro","molecular docking","natural product","sars-cov-2"],"locations":["Cryptoquindoline","Cryptospirolepine","Isoiguesterin"],"e_drugs":["10'-hydroxyusambarensine","Lopinavir","Ritonavir","Alkaloids","iguesterin","cryptospirolepine","20-epibryonolic acid","Terpenes"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496156303362,"score":394.25592},{"pmid":32362217,"title":"In silico study the inhibition of Angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from western Algeria.","text":["In silico study the inhibition of Angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from western Algeria.","The objective of this present study is to focus on the in silico study to screen for an alternative drug that can block the activity of the angiotensin converting enzyme 2 (ACE2) as a receptor for SARS-CoV-2, potential therapeutic target of the COVID-19 virus using natural compounds (Isothymol, Thymol, Limonene, P-cymene and gamma-terpinene) derived from the essential oil of the antiviral and antimicrobial plant Ammoides verticillata (Desf.) Briq. which is located in the occidental Algeria areas. This study reveals that Isothymol, a major component of this plant, gives the best docking scores, compared to, the co-crystallized inhibitor beta-D-mannose of the enzyme ACE2, to Captropil drug as good ACE2 inhibitor and to Chloroquine antiviral drug also involved in other mechanisms as inhibition of ACE2 cellular receptor. In silico (ADME), drug-likeness, PASS & P450 site of metabolism prediction, pharmacophore Mapper showed that the compound Isothymol has give a good tests results compared to the beta-D-mannose co-crystallized inhibitor, to Captopril and Chloroquine drugs. Also the other natural compounds gave good results. The Molecular Dynamics Simulation study showed good result for the Isotymol- ACE2 docked complex. This study revealed for the first time that Isothymol is a functional inhibitor of angiotensin converting enzyme 2 activity and the components of essential oils Ammoides verticillata can be used as a potential inhibitors to the ACE2 receptor of SARS-CoV-2.","J Biomol Struct Dyn","Abdelli, Imane","Hassani, Faical","Bekkel Brikci, Sohayb","Ghalem, Said","32362217"],"abstract":["The objective of this present study is to focus on the in silico study to screen for an alternative drug that can block the activity of the angiotensin converting enzyme 2 (ACE2) as a receptor for SARS-CoV-2, potential therapeutic target of the COVID-19 virus using natural compounds (Isothymol, Thymol, Limonene, P-cymene and gamma-terpinene) derived from the essential oil of the antiviral and antimicrobial plant Ammoides verticillata (Desf.) Briq. which is located in the occidental Algeria areas. This study reveals that Isothymol, a major component of this plant, gives the best docking scores, compared to, the co-crystallized inhibitor beta-D-mannose of the enzyme ACE2, to Captropil drug as good ACE2 inhibitor and to Chloroquine antiviral drug also involved in other mechanisms as inhibition of ACE2 cellular receptor. In silico (ADME), drug-likeness, PASS & P450 site of metabolism prediction, pharmacophore Mapper showed that the compound Isothymol has give a good tests results compared to the beta-D-mannose co-crystallized inhibitor, to Captopril and Chloroquine drugs. Also the other natural compounds gave good results. The Molecular Dynamics Simulation study showed good result for the Isotymol- ACE2 docked complex. This study revealed for the first time that Isothymol is a functional inhibitor of angiotensin converting enzyme 2 activity and the components of essential oils Ammoides verticillata can be used as a potential inhibitors to the ACE2 receptor of SARS-CoV-2."],"journal":"J Biomol Struct Dyn","authors":["Abdelli, Imane","Hassani, Faical","Bekkel Brikci, Sohayb","Ghalem, Said"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32362217","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1080/07391102.2020.1763199","keywords":["ammoides verticillata","angiotensin converting enzyme 2","covid-19","isothymol","molcular docking"],"locations":["Limonene","Algeria","Algeria"],"countries":["Algeria"],"countries_codes":["DZA|Algeria"],"e_drugs":["4-cymene","gamma-terpinene","carvacrol","Chloroquine","Thymol","Captopril","Oils, Volatile","Limonene"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496047251458,"score":384.7015},{"pmid":32410504,"title":"Marine natural compounds as potents inhibitors against the main protease of SARS-CoV-2. A molecular dynamic study.","text":["Marine natural compounds as potents inhibitors against the main protease of SARS-CoV-2. A molecular dynamic study.","Sever acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a single-stranded RNA (ssRNA) virus, responsible for severe acute respiratory disease (COVID-19). A large number of natural compounds are under trial for screening compounds, possessing potential inhibitory effect against the viral infection. Keeping in view the importance of marine compounds in antiviral activity, we investigated the potency of some marine natural products to target SARS-CoV-2 main protease (M(pro)) (PDB ID 6MO3). The crystallographic structure of M(pro) in an apo form was retrieved from Protein Data Bank and marine compounds from PubChem. These structures were prepared for docking and the complex with good docking score was subjected to molecular dynamic (MD) simulations for a period of 100ns. To measure the stability, flexibility, and average distance between the target and compounds, root means square deviations (RMSD), root means square fluctuation (RMSF), and the distance matrix were calculated. Among five marine compounds, C-1 (PubChem CID 11170714) exhibited good activity, interacting with the active site and surrounding residues, forming many hydrogen and hydrophobic interactions. The C-1 also attained a stable dynamic behavior, and the average distance between compound and target remains constant. In conclusion, marine natural compounds may be used as a potential inhibitor against SARS-CoV-2 for better management of COVID-19.","J Biomol Struct Dyn","Khan, Muhammad Tahir","Ali, Arif","Wang, Qiankun","Irfan, Muhammad","Khan, Abbas","Zeb, Muhammad Tariq","Zhang, Yu-Juan","Chinnasamy, Sathishkumar","Wei, Dong-Qing","32410504"],"abstract":["Sever acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a single-stranded RNA (ssRNA) virus, responsible for severe acute respiratory disease (COVID-19). A large number of natural compounds are under trial for screening compounds, possessing potential inhibitory effect against the viral infection. Keeping in view the importance of marine compounds in antiviral activity, we investigated the potency of some marine natural products to target SARS-CoV-2 main protease (M(pro)) (PDB ID 6MO3). The crystallographic structure of M(pro) in an apo form was retrieved from Protein Data Bank and marine compounds from PubChem. These structures were prepared for docking and the complex with good docking score was subjected to molecular dynamic (MD) simulations for a period of 100ns. To measure the stability, flexibility, and average distance between the target and compounds, root means square deviations (RMSD), root means square fluctuation (RMSF), and the distance matrix were calculated. Among five marine compounds, C-1 (PubChem CID 11170714) exhibited good activity, interacting with the active site and surrounding residues, forming many hydrogen and hydrophobic interactions. The C-1 also attained a stable dynamic behavior, and the average distance between compound and target remains constant. In conclusion, marine natural compounds may be used as a potential inhibitor against SARS-CoV-2 for better management of COVID-19."],"journal":"J Biomol Struct Dyn","authors":["Khan, Muhammad Tahir","Ali, Arif","Wang, Qiankun","Irfan, Muhammad","Khan, Abbas","Zeb, Muhammad Tariq","Zhang, Yu-Juan","Chinnasamy, Sathishkumar","Wei, Dong-Qing"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32410504","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1080/07391102.2020.1769733","keywords":["covid-19","dock","interactions","marine drugs"],"e_drugs":["Carbon"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666897319071580161,"score":375.39288}]}